Conjutivite alérgica perene estudo aberto com cromoglicato dissódico a 2 por cento

Galväo, Clóvis E. S; GIOSA, José T. B; Ribeiro, Lúcio F. M; Mello, Yara A. M. F; Mello, Joäo F. de.
Rev. bras. alergia imunopatol ; 22(5): 145-50, set.-out. 1999. tab
Artículo en Portugués | LILACS | ID: lil-279198

Documentos relacionados

  1. A double-masked study to compare the efficacy and safety of topical cromolyn for the treatment of allergic conjunctivitis.
  2. Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.
  3. Blood CD62L<sup>low</sup> inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab.
  4. Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma.
  5. Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype.
  6. Molecular and immunomodulatory actions of new antiasthmatic agents: Exploring the diversity of biologics in Th2 endotype asthma.
  7. A rational approach to compare and select biologic therapeutics in asthma.
  8. Unravelling the effects of omalizumab on fibrocytes.
  9. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients.
  10. [Dupilumab : a new treatment for severe T2 high asthma].